Provided by Tiger Trade Technology Pte. Ltd.

4D Molecular Therapeutics

10.06
+0.29002.97%
Post-market: 10.00-0.0563-0.56%18:46 EDT
Volume:837.07K
Turnover:8.21M
Market Cap:513.14M
PE:-4.16
High:10.10
Open:9.75
Low:9.53
Close:9.77
52wk High:12.34
52wk Low:2.88
Shares:51.01M
Float Shares:36.78M
Volume Ratio:1.17
T/O Rate:2.28%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4186
EPS(LYR):-2.4200
ROE:-27.57%
ROA:-17.34%
PB:1.01
PE(LYR):-4.16

Loading ...

4D Molecular price target lowered to $23 from $45 at Evercore ISI

TIPRANKS
·
Apr 13

4D Molecular Therapeutics Consolidates Financial Leadership Under New Role

TIPRANKS
·
Mar 31

4D Molecular Therapeutics names CFO Kristian Humer principal accounting officer

Reuters
·
Mar 31

4D Molecular Therapeutics Coverage Assumed by Jefferies at Buy

Dow Jones
·
Mar 31

U.S. RESEARCH ROUNDUP- Ferguson Enterprises, Hartford Insurance Group, JP Morgan

Reuters
·
Mar 30

4D Molecular Therapeutics VP Finance and Controller Ashoo Gupta disposes of USD 3,356 in common shares

Reuters
·
Mar 25

Reimbursement and Pricing Pressures Threaten Commercial Outlook for 4D Molecular Therapeutics’ Gene Therapies

TIPRANKS
·
Mar 20

4D Molecular Therapeutics Is Maintained at Outperform by RBC Capital

Dow Jones
·
Mar 19

4D Molecular Therapeutics (FDMT) Receives a Hold from Cantor Fitzgerald

TIPRANKS
·
Mar 19

RBC Raises Price Target on 4D Molecular Therapeutics to $35 From $32, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Mar 19

Chardan Capital Remains a Buy on 4D Molecular Therapeutics (FDMT)

TIPRANKS
·
Mar 19

4D Molecular Therapeutics publishes corporate presentation on 4D-150 retinal gene therapy program

Reuters
·
Mar 19

4D Molecular Therapeutics Q4 EPS $0.43 Beats $(0.82) Estimate, Sales $85.090M Beat $21.817M Estimate

Benzinga
·
Mar 19

4D Molecular Therapeutics FY 2025 R&D expenses rise 39% to USD 196 million, net loss narrows 13% to USD 140 million

Reuters
·
Mar 19

Press Release: 4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

Dow Jones
·
Mar 19

4D Molecular Therapeutics Inc expected to post a loss of 76 cents a share - Earnings Preview

Reuters
·
Feb 24

4D Molecular Therapeutics to Present at TD Cowen, Leerink and Barclays Healthcare Investor Conferences

Reuters
·
Feb 19

4D Molecular Therapeutics Grants 124,200 RSUs to New Employees

Reuters
·
Feb 14

4D Molecular Therapeutics Completes Enrollment for Phase 3 Wet AMD Trial of 4D-150

Reuters
·
Feb 09

4Dmt Completes Enrollment for 4Front-1 Phase 3 Clinical Trial of 4D-150 in Wet Amd

THOMSON REUTERS
·
Feb 09